Tag Archives | pharmacogenomics

Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates

Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See Chart below of Emerging Orphan drug […]

Continue Reading 0

Hot Biotech Sector: Mid-Caps Have Both M&A and Pipeline Premiums

Valuations Step-Up With More Deals  Prior to the acquisition of Pharmacyclics (PCYC) by Abbvie (ABBV) for $20B, the top price paid for an emerging biotech company was in the $10B range. Two additional companies among the mid-caps  were acquired in prior years: Cubist by Merck in December 2014 and Onyx by Amgen in 2013. M&A […]

Continue Reading 0

Biotechs Tag Along With Broad Market Rally: FBT Up 3%

Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall productivity is down. Jobless claims are down also tracking an improved […]

Continue Reading 0

Ignyta: Precision Medicine for Oncology Integrating Companion Diagnostics

Teva Deal Expands Portfolio and Diagnostic Capabilities Adding RXDX to Rayno Small Cap Portfolio Ignyta, Inc. (RXDX) is an emerging biopharmaceutical Company targeting new oncology drugs that inhibit Tyrosine kinase receptors (Trk) with integrated biomarker-based companion diagnostics for each product candidate. The Company has two clinical stage products in Phase 1:  RXDX-106 its lead product […]

Continue Reading 0

Snap-Back Rally In Biotech-But Lagging Other Sectors

Global Rally Today But Healthcare Sector Lags A Bit DOW up 1.49% at 17,976 NASDAQ Up 1.15% at 4947 Healthcare up 0.93% We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a takeover target. The Company has […]

Continue Reading 0